Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Treatment options for highly drug-resistant tuberculosis are limited. In this study in South Africa, a new agent, pretomanid, was combined with bedaquiline and linezolid for a 26-week course to treat extensively drug-resistant and complicated multidrug-resistant pulmonary TB. Although there were tox...
Saved in:
| Published in | The New England journal of medicine Vol. 382; no. 10; pp. 893 - 902 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Massachusetts Medical Society
05.03.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0028-4793 1533-4406 1533-4406 |
| DOI | 10.1056/NEJMoa1901814 |
Cover
Loading…
| Abstract | Treatment options for highly drug-resistant tuberculosis are limited. In this study in South Africa, a new agent, pretomanid, was combined with bedaquiline and linezolid for a 26-week course to treat extensively drug-resistant and complicated multidrug-resistant pulmonary TB. Although there were toxic effects, 90% of patients had favorable outcomes. |
|---|---|
| AbstractList | Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.
In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bactericidal activity against tuberculosis and to which there is little preexisting resistance. We evaluated the safety and efficacy of the drug combination for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects. The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriologic or clinical) or relapse during follow-up, which continued until 6 months after the end of treatment. Patients were classified as having a favorable outcome at 6 months if they had resolution of clinical disease, a negative culture status, and had not already been classified as having had an unfavorable outcome. Other efficacy end points and safety were also evaluated.
A total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points. At 6 months after the end of treatment in the intention-to-treat analysis, 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome. The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up. The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose reductions or interruptions in treatment with linezolid.
The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed. (Funded by the TB Alliance and others; ClinicalTrials.gov number, NCT02333799.). Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.BACKGROUNDPatients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bactericidal activity against tuberculosis and to which there is little preexisting resistance. We evaluated the safety and efficacy of the drug combination for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects. The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriologic or clinical) or relapse during follow-up, which continued until 6 months after the end of treatment. Patients were classified as having a favorable outcome at 6 months if they had resolution of clinical disease, a negative culture status, and had not already been classified as having had an unfavorable outcome. Other efficacy end points and safety were also evaluated.METHODSIn an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs - bedaquiline, pretomanid, and linezolid - that have bactericidal activity against tuberculosis and to which there is little preexisting resistance. We evaluated the safety and efficacy of the drug combination for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects. The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriologic or clinical) or relapse during follow-up, which continued until 6 months after the end of treatment. Patients were classified as having a favorable outcome at 6 months if they had resolution of clinical disease, a negative culture status, and had not already been classified as having had an unfavorable outcome. Other efficacy end points and safety were also evaluated.A total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points. At 6 months after the end of treatment in the intention-to-treat analysis, 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome. The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up. The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose reductions or interruptions in treatment with linezolid.RESULTSA total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points. At 6 months after the end of treatment in the intention-to-treat analysis, 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome. The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up. The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose reductions or interruptions in treatment with linezolid.The combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed. (Funded by the TB Alliance and others; ClinicalTrials.gov number, NCT02333799.).CONCLUSIONSThe combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed. (Funded by the TB Alliance and others; ClinicalTrials.gov number, NCT02333799.). Treatment options for highly drug-resistant tuberculosis are limited. In this study in South Africa, a new agent, pretomanid, was combined with bedaquiline and linezolid for a 26-week course to treat extensively drug-resistant and complicated multidrug-resistant pulmonary TB. Although there were toxic effects, 90% of patients had favorable outcomes. BackgroundPatients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.MethodsIn an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatment with three oral drugs — bedaquiline, pretomanid, and linezolid — that have bactericidal activity against tuberculosis and to which there is little preexisting resistance. We evaluated the safety and efficacy of the drug combination for 26 weeks in patients with extensively drug-resistant tuberculosis and patients with multidrug-resistant tuberculosis that was not responsive to treatment or for which a second-line regimen had been discontinued because of side effects. The primary end point was the incidence of an unfavorable outcome, defined as treatment failure (bacteriologic or clinical) or relapse during follow-up, which continued until 6 months after the end of treatment. Patients were classified as having a favorable outcome at 6 months if they had resolution of clinical disease, a negative culture status, and had not already been classified as having had an unfavorable outcome. Other efficacy end points and safety were also evaluated.ResultsA total of 109 patients were enrolled in the study and were included in the evaluation of efficacy and safety end points. At 6 months after the end of treatment in the intention-to-treat analysis, 11 patients (10%) had an unfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome. The 11 unfavorable outcomes were 7 deaths (6 during treatment and 1 from an unknown cause during follow-up), 1 withdrawal of consent during treatment, 2 relapses during follow-up, and 1 loss to follow-up. The expected linezolid toxic effects of peripheral neuropathy (occurring in 81% of patients) and myelosuppression (48%), although common, were manageable, often leading to dose reductions or interruptions in treatment with linezolid.ConclusionsThe combination of bedaquiline, pretomanid, and linezolid led to a favorable outcome at 6 months after the end of therapy in a high percentage of patients with highly drug-resistant forms of tuberculosis; some associated toxic effects were observed. (Funded by the TB Alliance and others; ClinicalTrials.gov number, NCT02333799.) |
| Author | Conradie, Francesca Bateson, Anna Olugbosi, Morounfolu Mendel, Carl M Everitt, Daniel Moreira, Joanna Ngubane, Nosipho Timm, Juliano Wills, Genevieve H Spigelman, Melvin Crook, Angela M Howell, Pauline Hunt, Robert Li, Mengchun Van Niekerk, Christo Diacon, Andreas H Egizi, Erica McHugh, Timothy D |
| Author_xml | – sequence: 1 givenname: Francesca surname: Conradie fullname: Conradie, Francesca organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 2 givenname: Andreas H surname: Diacon fullname: Diacon, Andreas H organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 3 givenname: Nosipho surname: Ngubane fullname: Ngubane, Nosipho organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 4 givenname: Pauline surname: Howell fullname: Howell, Pauline organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 5 givenname: Daniel surname: Everitt fullname: Everitt, Daniel organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 6 givenname: Angela M surname: Crook fullname: Crook, Angela M organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 7 givenname: Carl M surname: Mendel fullname: Mendel, Carl M organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 8 givenname: Erica surname: Egizi fullname: Egizi, Erica organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 9 givenname: Joanna surname: Moreira fullname: Moreira, Joanna organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 10 givenname: Juliano surname: Timm fullname: Timm, Juliano organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 11 givenname: Timothy D surname: McHugh fullname: McHugh, Timothy D organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 12 givenname: Genevieve H surname: Wills fullname: Wills, Genevieve H organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 13 givenname: Anna surname: Bateson fullname: Bateson, Anna organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 14 givenname: Robert surname: Hunt fullname: Hunt, Robert organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 15 givenname: Christo surname: Van Niekerk fullname: Van Niekerk, Christo organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 16 givenname: Mengchun surname: Li fullname: Li, Mengchun organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 17 givenname: Morounfolu surname: Olugbosi fullname: Olugbosi, Morounfolu organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London – sequence: 18 givenname: Melvin surname: Spigelman fullname: Spigelman, Melvin organization: From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) — all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32130813$$D View this record in MEDLINE/PubMed |
| BookMark | eNp10M9LwzAUB_AgE_dDj16lIIKXatKkbXqUOZ0yfyDzXNL0dXY0yUzaw_57o5uCg-WSw_u8l5fvEPW00YDQKcFXBMfJ9fPk8ckIkmHCCTtAAxJTGjKGkx4aYBzxkKUZ7aOhc0vsD2HZEerTiFDMCR2gbG5BtAp0G5gqmNaLj2Yd3NpuEb6Bq10rfOG1a5TRwq6DeVeAlV1jfOkYHVaicXCyvUfo_W4yH0_D2cv9w_hmFkoWJ20oATMJFEcF-BeTipYFTQGYLGJKUiFjllHJiOBEpIUHaclxUkVlWoqYM1rSEbrczF1Z89mBa3NVOwlNIzSYzuURTQlP_Gzu6fkOXZrOar_dj4oZxT6dETrbqq5QUOYrWyv_ufw3FA_CDZDWOGeh-iME59-h5_9C957ueFm3oq2Nbq2om71dF5supVyuYan2uC9x6o5Q |
| CitedBy_id | crossref_primary_10_1007_s40262_023_01217_7 crossref_primary_10_1016_j_bmcl_2025_130108 crossref_primary_10_1021_acsinfecdis_4c00743 crossref_primary_10_1016_j_bioorg_2023_106591 crossref_primary_10_1164_rccm_202108_1976OC crossref_primary_10_1177_03000605221148416 crossref_primary_10_1016_j_cegh_2024_101604 crossref_primary_10_4103_lungindia_lungindia_431_24 crossref_primary_10_1039_D2BM01835G crossref_primary_10_1097_FTD_0000000000001164 crossref_primary_10_3390_ph16060784 crossref_primary_10_1016_j_pupt_2022_102132 crossref_primary_10_1016_j_ijid_2022_09_012 crossref_primary_10_1016_j_mehy_2024_111396 crossref_primary_10_1016_j_jctube_2020_100192 crossref_primary_10_3390_ijerph20032640 crossref_primary_10_3390_antibiotics11010019 crossref_primary_10_1080_22221751_2023_2178243 crossref_primary_10_3389_fmed_2021_723667 crossref_primary_10_1128_AAC_00024_21 crossref_primary_10_1016_S2666_5247_21_00175_0 crossref_primary_10_1371_journal_ppat_1011663 crossref_primary_10_1164_rccm_202212_2262ED crossref_primary_10_1093_cid_ciaf035 crossref_primary_10_1016_S1473_3099_24_00223_8 crossref_primary_10_1136_bmjopen_2021_058606 crossref_primary_10_1128_AAC_00253_21 crossref_primary_10_1016_j_ijid_2021_01_062 crossref_primary_10_1093_inthealth_ihac016 crossref_primary_10_4103_apjtm_apjtm_244_24 crossref_primary_10_1016_j_ejmech_2023_115351 crossref_primary_10_1111_hiv_13318 crossref_primary_10_3389_fcimb_2022_1029044 crossref_primary_10_1097_QCO_0000000000000899 crossref_primary_10_1128_aac_02091_21 crossref_primary_10_1016_j_micpath_2023_106438 crossref_primary_10_1021_acs_biochem_4c00557 crossref_primary_10_3390_antibiotics12071171 crossref_primary_10_1371_journal_pone_0292106 crossref_primary_10_3201_eid2701_203766 crossref_primary_10_3389_fmicb_2024_1439814 crossref_primary_10_3389_fphar_2022_1032674 crossref_primary_10_7759_cureus_37033 crossref_primary_10_1016_j_arbr_2020_03_014 crossref_primary_10_1080_14787210_2023_2207820 crossref_primary_10_1128_cmr_00180_19 crossref_primary_10_1111_imr_12959 crossref_primary_10_3389_fimmu_2021_645485 crossref_primary_10_1183_13993003_00436_2024 crossref_primary_10_1007_s40475_023_00287_8 crossref_primary_10_1055_a_1204_6309 crossref_primary_10_1002_psp4_12591 crossref_primary_10_1016_j_jctube_2020_100175 crossref_primary_10_1016_j_cmi_2021_08_007 crossref_primary_10_1016_j_tetlet_2021_153484 crossref_primary_10_1128_aac_00357_24 crossref_primary_10_37489_0235_2990_2023_68_11_12_67_74 crossref_primary_10_1186_s12992_024_01047_7 crossref_primary_10_4103_lungindia_lungindia_556_22 crossref_primary_10_1007_s11094_024_03203_0 crossref_primary_10_22625_2072_6732_2025_17_1_26_35 crossref_primary_10_1002_chem_202102809 crossref_primary_10_5005_ijcdas_62_1_5 crossref_primary_10_1128_AAC_00974_21 crossref_primary_10_1128_AAC_01178_20 crossref_primary_10_1371_journal_pone_0272770 crossref_primary_10_1128_aac_00035_23 crossref_primary_10_3390_antibiotics10080981 crossref_primary_10_2147_IDR_S365371 crossref_primary_10_1007_s15033_022_3422_z crossref_primary_10_1128_aac_01829_21 crossref_primary_10_2147_DDDT_S281639 crossref_primary_10_1093_infdis_jiab101 crossref_primary_10_36416_1806_3756_e20210384 crossref_primary_10_1055_a_2182_1609 crossref_primary_10_1056_NEJMe2214707 crossref_primary_10_1164_rccm_202007_2974ED crossref_primary_10_1128_jcm_01832_22 crossref_primary_10_1007_s00018_023_04914_5 crossref_primary_10_1080_17460441_2022_2114451 crossref_primary_10_1093_cid_ciae388 crossref_primary_10_1016_j_mmifmc_2022_02_001 crossref_primary_10_1093_cid_ciae145 crossref_primary_10_1128_AAC_00450_20 crossref_primary_10_1016_j_jctube_2022_100321 crossref_primary_10_1128_mbio_00598_23 crossref_primary_10_1164_rccm_202202_0393ED crossref_primary_10_3390_ijerph18094663 crossref_primary_10_1093_cid_ciad051 crossref_primary_10_1128_spectrum_02744_24 crossref_primary_10_3390_ph14050461 crossref_primary_10_1186_s12879_023_08644_8 crossref_primary_10_1186_s12939_024_02368_0 crossref_primary_10_1016_j_bioorg_2024_107511 crossref_primary_10_1186_s12889_021_11427_y crossref_primary_10_3390_pathogens12081026 crossref_primary_10_54962_ankemderg_1405325 crossref_primary_10_2147_IDR_S425743 crossref_primary_10_3389_fcimb_2020_611683 crossref_primary_10_1016_j_ijtb_2020_09_005 crossref_primary_10_1016_j_biopha_2024_117153 crossref_primary_10_1177_10915818221113295 crossref_primary_10_1080_14656566_2021_1967930 crossref_primary_10_1002_psp4_13117 crossref_primary_10_1371_journal_pgph_0000313 crossref_primary_10_3390_antibiotics12030628 crossref_primary_10_1186_s13063_023_07354_5 crossref_primary_10_1002_cpt_2261 crossref_primary_10_2174_1574885519666230830125139 crossref_primary_10_1007_s40267_020_00743_9 crossref_primary_10_1038_d41586_020_03406_x crossref_primary_10_1164_rccm_202208_1475OC crossref_primary_10_3390_ijms24021142 crossref_primary_10_1038_s41467_024_50781_4 crossref_primary_10_1007_s00108_023_01523_z crossref_primary_10_1016_j_jmii_2024_08_002 crossref_primary_10_1080_21505594_2022_2150449 crossref_primary_10_3389_fimmu_2020_00891 crossref_primary_10_1016_j_tube_2022_102207 crossref_primary_10_3390_ijerph18094685 crossref_primary_10_1016_j_toxrep_2022_04_021 crossref_primary_10_1021_acs_jmedchem_0c01833 crossref_primary_10_3389_fmicb_2022_1056608 crossref_primary_10_1371_journal_pgph_0000567 crossref_primary_10_2147_IDR_S499816 crossref_primary_10_1016_S2214_109X_24_00088_3 crossref_primary_10_1128_aac_00962_24 crossref_primary_10_1016_j_xcrm_2022_100737 crossref_primary_10_1007_s40262_024_01442_8 crossref_primary_10_1016_j_jctube_2021_100285 crossref_primary_10_1038_s41598_022_25827_6 crossref_primary_10_3390_microorganisms13040722 crossref_primary_10_1056_NEJMe2300413 crossref_primary_10_1016_j_crphar_2022_100128 crossref_primary_10_4103_jfmpc_jfmpc_756_20 crossref_primary_10_1016_j_jctube_2024_100470 crossref_primary_10_1128_CMR_00141_20 crossref_primary_10_3390_antibiotics10121515 crossref_primary_10_1093_jac_dkac070 crossref_primary_10_1093_cid_ciac176 crossref_primary_10_36303_SAGP_1204 crossref_primary_10_1016_j_jctube_2024_100472 crossref_primary_10_3390_microorganisms9051074 crossref_primary_10_1093_pubmed_fdac124 crossref_primary_10_1038_s41598_021_98980_z crossref_primary_10_1093_ofid_ofac500 crossref_primary_10_1155_2024_5542658 crossref_primary_10_1016_j_nantod_2023_101942 crossref_primary_10_1128_aac_00766_23 crossref_primary_10_1056_NEJMc2119461 crossref_primary_10_1128_aac_00789_23 crossref_primary_10_1183_13993003_00639_2023 crossref_primary_10_3390_pathogens13121045 crossref_primary_10_1056_NEJMc2009939 crossref_primary_10_1093_jac_dkac067 crossref_primary_10_1093_jac_dkad276 crossref_primary_10_2478_pneum_2022_0029 crossref_primary_10_3389_fmed_2023_1304857 crossref_primary_10_1016_j_jgar_2022_09_001 crossref_primary_10_1002_advs_202400176 crossref_primary_10_1016_j_cmi_2023_07_013 crossref_primary_10_3390_medicina58020188 crossref_primary_10_60099_prijnr_2025_270467 crossref_primary_10_3390_tropicalmed8070338 crossref_primary_10_7326_M23_0757 crossref_primary_10_3389_fvets_2022_891429 crossref_primary_10_1007_s11298_021_2038_7 crossref_primary_10_3390_antibiotics12040714 crossref_primary_10_35366_112949 crossref_primary_10_1097_QAI_0000000000003150 crossref_primary_10_20411_pai_v9i2_705 crossref_primary_10_1016_j_drudis_2024_103955 crossref_primary_10_3390_life12111774 crossref_primary_10_1128_JB_00411_20 crossref_primary_10_1183_20734735_0232_2024 crossref_primary_10_1021_acs_jmedchem_4c01302 crossref_primary_10_1016_j_phrs_2022_106336 crossref_primary_10_4103_1995_7645_329004 crossref_primary_10_1186_s12916_024_03633_3 crossref_primary_10_1016_j_cell_2023_01_043 crossref_primary_10_1016_j_ejmech_2022_114935 crossref_primary_10_1038_s41579_022_00731_y crossref_primary_10_1016_j_micpath_2025_107287 crossref_primary_10_1093_jac_dkad252 crossref_primary_10_3389_fmicb_2023_1112491 crossref_primary_10_1016_j_ejmech_2021_113568 crossref_primary_10_22328_2077_9828_2022_14_4_29_35 crossref_primary_10_3389_fphar_2024_1338902 crossref_primary_10_1056_NEJMoa2119430 crossref_primary_10_1080_00958972_2021_2007892 crossref_primary_10_1093_cid_ciad596 crossref_primary_10_1172_JCI145107 crossref_primary_10_7554_eLife_96190 crossref_primary_10_1016_S1473_3099_24_00144_0 crossref_primary_10_3201_eid2809_220458 crossref_primary_10_25259_JPATS_2_2024 crossref_primary_10_1371_journal_pgph_0001337 crossref_primary_10_1016_j_lpm_2022_104112 crossref_primary_10_1093_ofid_ofaa653 crossref_primary_10_3390_antibiotics14010007 crossref_primary_10_1002_14651858_CD014841 crossref_primary_10_4103_jpdtsm_jpdtsm_117_23 crossref_primary_10_1038_s41467_024_48448_1 crossref_primary_10_1128_spectrum_02181_24 crossref_primary_10_1186_s12879_020_05075_7 crossref_primary_10_1080_17476348_2024_2418932 crossref_primary_10_1002_phar_2909 crossref_primary_10_1128_AAC_02418_20 crossref_primary_10_1080_17460441_2023_2157811 crossref_primary_10_1021_acsinfecdis_4c00025 crossref_primary_10_1128_aac_01010_23 crossref_primary_10_1080_17512433_2023_2148653 crossref_primary_10_1016_j_tube_2021_102087 crossref_primary_10_3390_pharmaceutics15122758 crossref_primary_10_1007_s11095_022_03393_w crossref_primary_10_1093_infdis_jiae332 crossref_primary_10_1016_j_coph_2021_05_007 crossref_primary_10_1111_cea_14104 crossref_primary_10_3389_fimmu_2020_557809 crossref_primary_10_3390_pathogens12121394 crossref_primary_10_1186_s12913_021_07043_6 crossref_primary_10_1016_j_nmni_2024_101437 crossref_primary_10_1093_cid_ciae305 crossref_primary_10_1093_cid_ciac485 crossref_primary_10_1016_j_jve_2021_100058 crossref_primary_10_1093_cid_ciad694 crossref_primary_10_1016_j_jctube_2024_100449 crossref_primary_10_1002_cbdv_202400389 crossref_primary_10_1016_j_jmgm_2023_108404 crossref_primary_10_1093_jac_dkac019 crossref_primary_10_51699_ijhsms_v3i3_58 crossref_primary_10_1136_bmjgh_2021_007182 crossref_primary_10_3390_pharmaceutics14040753 crossref_primary_10_3201_eid2711_210726 crossref_primary_10_1128_AAC_00709_20 crossref_primary_10_46234_ccdcw2021_053 crossref_primary_10_12688_wellcomeopenres_16783_1 crossref_primary_10_1016_j_ijid_2022_11_007 crossref_primary_10_1002_adtp_202000113 crossref_primary_10_1016_j_jctube_2023_100376 crossref_primary_10_1016_j_sbi_2023_102670 crossref_primary_10_1056_NEJMoa2117166 crossref_primary_10_1093_infdis_jiae438 crossref_primary_10_1080_14756366_2024_2403744 crossref_primary_10_2147_IDR_S467971 crossref_primary_10_1056_NEJMe2208554 crossref_primary_10_1093_infdis_jiab043 crossref_primary_10_1093_ofid_ofab551 crossref_primary_10_1016_j_ijpharm_2022_121893 crossref_primary_10_1128_AAC_01381_21 crossref_primary_10_1038_s41573_024_00897_5 crossref_primary_10_1021_acs_jmedchem_3c01892 crossref_primary_10_1371_journal_pdig_0000059 crossref_primary_10_1093_cid_ciad314 crossref_primary_10_1038_s41467_022_33736_5 crossref_primary_10_1056_NEJMe2200966 crossref_primary_10_1016_S2666_5247_23_00172_6 crossref_primary_10_1093_cid_ciad312 crossref_primary_10_1186_s13063_023_07520_9 crossref_primary_10_1016_j_ijtb_2022_06_006 crossref_primary_10_1055_a_1266_5207 crossref_primary_10_1021_acs_oprd_4c00014 crossref_primary_10_1093_ofid_ofac630 crossref_primary_10_1016_j_jctube_2024_100426 crossref_primary_10_1016_j_tube_2023_102346 crossref_primary_10_3389_fitd_2022_834013 crossref_primary_10_1183_20734735_0028_2023 crossref_primary_10_1186_s12879_022_07861_x crossref_primary_10_5005_jp_journals_10071_24783 crossref_primary_10_5588_ijtldopen_23_0527 crossref_primary_10_3390_pathogens11040381 crossref_primary_10_2147_IDR_S443897 crossref_primary_10_1016_j_ejmech_2024_116326 crossref_primary_10_1128_JCM_01582_19 crossref_primary_10_1016_j_cmi_2022_07_026 crossref_primary_10_3390_molecules25102431 crossref_primary_10_1128_aac_01562_23 crossref_primary_10_1007_s00228_024_03749_8 crossref_primary_10_1016_S2666_5247_24_00149_6 crossref_primary_10_1093_jpids_piac047 crossref_primary_10_3389_fphar_2021_749945 crossref_primary_10_1016_j_ijantimicag_2023_107048 crossref_primary_10_1183_13993003_00641_2021 crossref_primary_10_1021_acsinfecdis_3c00655 crossref_primary_10_1093_jac_dkae405 crossref_primary_10_1128_AAC_01412_21 crossref_primary_10_1038_s41467_023_39300_z crossref_primary_10_36416_1806_3756_e20240391 crossref_primary_10_1093_milmed_usae104 crossref_primary_10_4103_amhs_amhs_33_20 crossref_primary_10_1016_j_jddst_2021_103069 crossref_primary_10_1093_cid_ciad659 crossref_primary_10_1093_cid_ciac208 crossref_primary_10_1111_resp_14887 crossref_primary_10_1016_j_jinf_2024_106291 crossref_primary_10_1021_acs_jmedchem_2c00227 crossref_primary_10_1080_24745332_2021_1875936 crossref_primary_10_1093_cid_ciad653 crossref_primary_10_1016_j_ijantimicag_2021_106509 crossref_primary_10_1016_j_diagmicrobio_2022_115714 crossref_primary_10_1016_j_medcle_2020_08_009 crossref_primary_10_1093_jpids_piac051 crossref_primary_10_36488_cmac_2021_1_27_42 crossref_primary_10_1080_17568919_2024_2403963 crossref_primary_10_1097_MD_0000000000030405 crossref_primary_10_3390_jor1020013 crossref_primary_10_1128_aac_01034_22 crossref_primary_10_1186_s13063_022_06793_w crossref_primary_10_1016_S1473_3099_24_00512_7 crossref_primary_10_1038_s41591_021_01442_2 crossref_primary_10_1038_s42004_021_00501_6 crossref_primary_10_21292_2075_1230_2022_100_11_56_65 crossref_primary_10_1371_journal_pgph_0001287 crossref_primary_10_1128_aac_00408_22 crossref_primary_10_1128_mra_00745_24 crossref_primary_10_3390_antibiotics11111622 crossref_primary_10_1183_23120541_00622_2021 crossref_primary_10_3389_fcimb_2020_603382 crossref_primary_10_7554_eLife_96190_3 crossref_primary_10_1371_journal_pone_0276457 crossref_primary_10_1016_j_cclet_2023_108464 crossref_primary_10_1016_j_mib_2022_102191 crossref_primary_10_1093_ofid_ofad534 crossref_primary_10_7554_eLife_80218 crossref_primary_10_1186_s13063_021_05491_3 crossref_primary_10_1007_s40265_022_01817_w crossref_primary_10_1128_aac_02108_21 crossref_primary_10_1016_S2352_3018_25_00040_2 crossref_primary_10_1136_bmjopen_2021_051521 crossref_primary_10_3389_fphar_2022_1081123 crossref_primary_10_1016_j_ijregi_2022_09_005 crossref_primary_10_1128_AAC_00706_21 crossref_primary_10_1056_NEJMe2000860 crossref_primary_10_3390_microorganisms10030514 crossref_primary_10_1038_s41598_023_30873_9 crossref_primary_10_1093_jacamr_dlac029 crossref_primary_10_1186_s40249_021_00913_5 crossref_primary_10_1016_j_cpha_2023_02_006 crossref_primary_10_1093_cid_ciab335 crossref_primary_10_5588_ijtldopen_24_0094 crossref_primary_10_1093_cid_ciab699 crossref_primary_10_1080_17425255_2021_1836158 crossref_primary_10_1016_S0992_5945_23_00178_2 crossref_primary_10_1016_j_ijtb_2023_09_011 crossref_primary_10_7759_cureus_55190 crossref_primary_10_1097_MCP_0000000000000866 crossref_primary_10_1128_aac_01275_23 crossref_primary_10_1186_s13063_022_06331_8 crossref_primary_10_3389_fcimb_2023_1225341 crossref_primary_10_2147_IDR_S257145 crossref_primary_10_3390_ph16111575 crossref_primary_10_1038_s41598_021_98862_4 crossref_primary_10_1128_aac_01915_21 crossref_primary_10_1016_j_ejmcr_2024_100183 crossref_primary_10_1016_j_ejps_2024_106915 crossref_primary_10_1016_j_jiph_2023_11_012 crossref_primary_10_1016_j_chembiol_2023_12_002 crossref_primary_10_1016_j_jiph_2023_11_018 crossref_primary_10_1016_j_ijid_2023_08_001 crossref_primary_10_1016_j_jgar_2022_01_026 crossref_primary_10_1021_acs_jmedchem_9b02075 crossref_primary_10_23736_S2784_8477_23_02066_1 crossref_primary_10_1097_WCO_0000000000001193 crossref_primary_10_3390_ph15050576 crossref_primary_10_1080_07853890_2022_2163053 crossref_primary_10_1080_14787210_2024_2303032 crossref_primary_10_1111_bcp_15193 crossref_primary_10_2174_1570163820666230222151558 crossref_primary_10_36290_csf_2020_028 crossref_primary_10_1093_cid_ciac528 crossref_primary_10_1186_s13063_024_07946_9 crossref_primary_10_3389_fcimb_2022_932556 crossref_primary_10_1016_S2213_2600_23_00389_2 crossref_primary_10_1016_j_cmi_2023_02_013 crossref_primary_10_1126_scitranslmed_adi4000 crossref_primary_10_1051_medsci_2023091 crossref_primary_10_1164_rccm_202211_2125OC crossref_primary_10_1126_sciadv_add5907 crossref_primary_10_21292_2075_1230_2021_99_6_54_60 crossref_primary_10_1002_chem_202301513 crossref_primary_10_1016_j_jctube_2020_100201 crossref_primary_10_1080_24745332_2022_2039499 crossref_primary_10_1159_000516392 crossref_primary_10_2147_IDR_S419996 crossref_primary_10_1007_s40262_021_00997_0 crossref_primary_10_1186_s12879_021_05870_w crossref_primary_10_1038_d41586_024_02094_1 crossref_primary_10_1146_annurev_med_100622_024848 crossref_primary_10_1016_j_jinf_2023_06_014 crossref_primary_10_1371_journal_pgph_0002283 crossref_primary_10_1007_s00044_024_03287_z crossref_primary_10_1093_cid_ciac511 crossref_primary_10_1098_rstb_2022_0039 crossref_primary_10_1016_j_medcli_2020_08_018 crossref_primary_10_1016_S0140_6736_23_01379_X crossref_primary_10_1002_jcph_2424 crossref_primary_10_1183_13993003_01925_2021 crossref_primary_10_3389_fcimb_2022_980844 crossref_primary_10_1002_slct_202101973 crossref_primary_10_1155_2024_6458900 crossref_primary_10_15212_ZOONOSES_2021_0021 crossref_primary_10_3389_fcimb_2022_997283 crossref_primary_10_1016_j_jctube_2023_100407 crossref_primary_10_1093_infdis_jiaf005 crossref_primary_10_4102_sajhivmed_v23i1_1396 crossref_primary_10_1016_j_jctube_2023_100408 crossref_primary_10_1183_20734735_0177_2024 crossref_primary_10_3389_fimmu_2024_1411827 crossref_primary_10_1093_cid_ciaa1894 crossref_primary_10_2174_1389450124666230505145335 crossref_primary_10_2174_1871526523666230309110705 crossref_primary_10_3389_fcimb_2021_707244 crossref_primary_10_1177_10600280211031390 crossref_primary_10_3389_fpubh_2022_967311 crossref_primary_10_1021_acsomega_2c05511 crossref_primary_10_1016_j_jctube_2023_100405 crossref_primary_10_1016_j_ijtb_2020_11_010 crossref_primary_10_1136_bmjopen_2023_078379 crossref_primary_10_1016_j_ijpharm_2024_123920 crossref_primary_10_1038_s41467_024_54072_w crossref_primary_10_2147_IDR_S469509 crossref_primary_10_1128_spectrum_00090_23 crossref_primary_10_3389_fcimb_2023_1258561 crossref_primary_10_1055_s_0042_1751375 crossref_primary_10_1128_AAC_01174_20 crossref_primary_10_1002_14651858_CD014841_pub2 crossref_primary_10_1016_S0140_6736_22_01883_9 crossref_primary_10_1371_journal_pone_0296448 crossref_primary_10_1055_a_1934_8303 crossref_primary_10_1371_journal_pone_0236264 crossref_primary_10_1039_D3MD00201B crossref_primary_10_1002_ddr_22063 crossref_primary_10_1128_AAC_01948_20 crossref_primary_10_3389_fmicb_2021_655653 crossref_primary_10_1128_aac_00898_22 crossref_primary_10_1055_a_1493_1206 crossref_primary_10_1002_cmdc_202300593 crossref_primary_10_1080_22297928_2021_1921616 crossref_primary_10_1128_mbio_03496_22 crossref_primary_10_1136_bcr_2021_245612 crossref_primary_10_1016_j_ijtb_2023_04_011 crossref_primary_10_1039_D3MD00019B crossref_primary_10_5582_ddt_2022_01024 crossref_primary_10_1016_j_jaad_2021_12_064 crossref_primary_10_1128_msphere_00369_22 crossref_primary_10_2174_0115680266286294240610102911 crossref_primary_10_1186_s13756_021_00995_8 crossref_primary_10_61474_ncs_2023_00027 crossref_primary_10_1093_cid_ciab992 crossref_primary_10_1016_j_nantod_2024_102414 crossref_primary_10_3389_fmicb_2022_775030 crossref_primary_10_1371_journal_pone_0309034 crossref_primary_10_3390_microorganisms10071421 crossref_primary_10_1002_minf_202100002 crossref_primary_10_1016_j_intimp_2024_111937 crossref_primary_10_1021_acsinfecdis_1c00643 crossref_primary_10_3390_app10165704 crossref_primary_10_1183_13993003_03300_2020 crossref_primary_10_1128_aac_01542_24 crossref_primary_10_18772_26180197_2023_v5n2a8 crossref_primary_10_1016_j_opresp_2024_100333 crossref_primary_10_5005_jp_journals_11007_0005 crossref_primary_10_1111_tmi_13814 crossref_primary_10_7868_S2587667822020017 crossref_primary_10_1136_bmjopen_2020_047185 crossref_primary_10_1159_000539410 crossref_primary_10_1371_journal_pone_0281097 crossref_primary_10_3389_fmicb_2020_559469 crossref_primary_10_1021_acsomega_2c05307 crossref_primary_10_21292_2075_1230_2020_98_12_57_66 crossref_primary_10_3390_ijms23020771 crossref_primary_10_1016_j_monrhu_2022_01_005 crossref_primary_10_1183_23120541_00628_2022 crossref_primary_10_1016_S0140_6736_22_02078_5 crossref_primary_10_1186_s40249_021_00819_2 crossref_primary_10_3389_fphar_2022_1021216 crossref_primary_10_4103_ijmy_ijmy_131_23 crossref_primary_10_17816_EID312900 crossref_primary_10_1093_cid_ciaa526 crossref_primary_10_1007_s40121_022_00750_5 crossref_primary_10_4103_ijmy_ijmy_88_23 crossref_primary_10_1016_j_ijtb_2024_06_008 crossref_primary_10_3390_pathogens11121420 crossref_primary_10_3390_pharmaceutics13081309 crossref_primary_10_1016_j_cels_2021_08_004 crossref_primary_10_3389_fcimb_2022_1085946 crossref_primary_10_12677_ACM_2023_134937 crossref_primary_10_1164_rccm_202107_1779OC crossref_primary_10_1016_j_tube_2021_102104 crossref_primary_10_1128_spectrum_00465_23 crossref_primary_10_1016_j_bioorg_2024_107699 crossref_primary_10_36740_WLek202107117 crossref_primary_10_1016_j_cmi_2023_03_021 crossref_primary_10_1128_aac_01399_22 crossref_primary_10_1371_journal_pcbi_1010823 crossref_primary_10_1093_cid_ciac932 crossref_primary_10_1080_22221751_2021_2006578 crossref_primary_10_1016_j_jsps_2022_01_015 crossref_primary_10_1038_s41522_021_00210_x crossref_primary_10_1371_journal_pone_0271102 crossref_primary_10_21292_2075_1230_2021_99_2_58_66 crossref_primary_10_1021_acs_jmedchem_2c01064 crossref_primary_10_1208_s12249_023_02585_w crossref_primary_10_2147_IDR_S375694 crossref_primary_10_1016_j_ijantimicag_2023_106953 crossref_primary_10_4155_fmc_2021_0010 crossref_primary_10_1183_13993003_00303_2024 crossref_primary_10_1016_S0140_6736_22_02161_4 crossref_primary_10_1016_j_bmcl_2020_127655 crossref_primary_10_1016_j_jiph_2021_09_030 crossref_primary_10_4103_jalh_jalh_58_24 crossref_primary_10_3389_fmed_2023_1265923 crossref_primary_10_3389_ftubr_2024_1435344 crossref_primary_10_1016_j_actatropica_2024_107365 crossref_primary_10_35366_117938 crossref_primary_10_1016_j_cmi_2024_06_016 crossref_primary_10_1021_acsmedchemlett_3c00570 crossref_primary_10_1111_bcp_15102 crossref_primary_10_4155_fmc_2021_0249 crossref_primary_10_1128_aac_00132_22 crossref_primary_10_1128_aac_00190_24 crossref_primary_10_1128_aac_01294_22 crossref_primary_10_1111_bcp_16318 crossref_primary_10_1016_S1473_3099_21_00811_2 crossref_primary_10_1016_j_tetlet_2022_153659 crossref_primary_10_1016_j_bmc_2024_118025 crossref_primary_10_1038_s41467_022_29832_1 crossref_primary_10_1038_s41598_021_84827_0 crossref_primary_10_3390_pathogens11060636 crossref_primary_10_20517_ohir_2024_03 crossref_primary_10_1371_journal_pone_0310773 crossref_primary_10_1038_s41467_023_43937_1 crossref_primary_10_1128_aac_01655_22 crossref_primary_10_2147_DDDT_S409604 crossref_primary_10_1021_acs_molpharmaceut_1c00791 crossref_primary_10_3389_fmed_2021_669509 crossref_primary_10_1128_AAC_01121_20 crossref_primary_10_1016_j_ejmech_2021_114066 crossref_primary_10_1099_mgen_0_000956 crossref_primary_10_1038_s41572_024_00504_2 crossref_primary_10_1093_ofid_ofad177 crossref_primary_10_1016_S0140_6736_24_02479_6 crossref_primary_10_1002_jia2_25698 crossref_primary_10_1016_j_drudis_2021_09_003 crossref_primary_10_2139_ssrn_3927770 crossref_primary_10_1128_aac_00854_24 crossref_primary_10_1128_mbio_01672_22 crossref_primary_10_1164_rccm_202303_0373ED crossref_primary_10_1093_infdis_jiaf088 crossref_primary_10_1021_jacs_2c08816 crossref_primary_10_1038_s41591_024_02840_y crossref_primary_10_3389_fphar_2023_1150243 crossref_primary_10_55544_jrasb_2_3_31 crossref_primary_10_1097_QAI_0000000000002940 crossref_primary_10_1186_s13063_021_05388_1 crossref_primary_10_1016_j_ejmech_2021_114059 crossref_primary_10_1007_s11904_020_00529_8 crossref_primary_10_1016_j_arbres_2020_03_021 crossref_primary_10_3390_app10072605 crossref_primary_10_1089_mdr_2021_0441 crossref_primary_10_1089_mdr_2024_0045 crossref_primary_10_1093_ofid_ofae257 crossref_primary_10_1016_j_jmii_2023_04_009 crossref_primary_10_1097_MOP_0000000000001226 crossref_primary_10_1186_s12879_022_07846_w crossref_primary_10_1038_s41579_024_01025_1 crossref_primary_10_1080_17476348_2021_1828069 crossref_primary_10_1039_D0DT01365J crossref_primary_10_1073_pnas_2417525122 crossref_primary_10_1002_cpz1_70118 crossref_primary_10_1007_s00408_024_00732_z crossref_primary_10_7759_cureus_64496 crossref_primary_10_1038_s41467_025_56888_6 crossref_primary_10_1172_JCI173156 crossref_primary_10_1016_S1877_1203_23_00019_8 crossref_primary_10_1084_jem_20200887 crossref_primary_10_1183_13993003_02250_2020 |
| Cites_doi | 10.1126/science.1164571 10.1128/AAC.01393-08 10.1056/NEJMoa1315817 10.5588/ijtld.11.0153 10.1016/S2213-2600(18)30235-2 10.1016/S0140-6736(18)31644-1 10.3343/alm.2018.38.6.563 10.1056/NEJMoa1201964 10.3201/eid2505.181823 10.3201/eid1903.120998 10.1128/AAC.49.6.2289-2293.2005 10.1056/NEJMoa1811867 10.4161/cib.2.3.7926 10.1183/13993003.00544-2018 10.1056/NEJMoa1314210 10.1016/j.ebiom.2018.01.005 10.1016/S0140-6736(06)69573-1 10.1056/NEJMoa1407426 10.1183/13993003.00724-2015 10.1038/35016103 10.1212/01.wnl.0000187119.33075.41 10.1016/S0140-6736(12)61080-0 |
| ContentType | Journal Article |
| Contributor | Canseco, Julio Ortiz Solanki, Priya Greyling, Lize Upton, Caryn Eriksson, Michelle Vanker, Naadira Fabiane, Stella Maris Mvuna, Nokuphiwa |
| Contributor_xml | – sequence: 1 givenname: Nokuphiwa surname: Mvuna fullname: Mvuna, Nokuphiwa – sequence: 2 givenname: Caryn surname: Upton fullname: Upton, Caryn – sequence: 3 givenname: Naadira surname: Vanker fullname: Vanker, Naadira – sequence: 4 givenname: Lize surname: Greyling fullname: Greyling, Lize – sequence: 5 givenname: Michelle surname: Eriksson fullname: Eriksson, Michelle – sequence: 6 givenname: Stella Maris surname: Fabiane fullname: Fabiane, Stella Maris – sequence: 7 givenname: Julio Ortiz surname: Canseco fullname: Canseco, Julio Ortiz – sequence: 8 givenname: Priya surname: Solanki fullname: Solanki, Priya |
| Copyright | Copyright © 2020 Massachusetts Medical Society. All rights reserved. Copyright © 2020 Massachusetts Medical Society. |
| Copyright_xml | – notice: Copyright © 2020 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2020 Massachusetts Medical Society. |
| CorporateAuthor | Nix-TB Trial Team |
| CorporateAuthor_xml | – name: Nix-TB Trial Team |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 |
| DOI | 10.1056/NEJMoa1901814 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Nursing & Allied Health Database Proquest Health and Medical Complete ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection eLibrary ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep SciTech Premium Collection New England Journal of Medicine ProQuest Biological Science Collection Consumer Health Database Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 902 |
| ExternalDocumentID | 32130813 10_1056_NEJMoa1901814 NJ202003053821005 |
| Genre | Original Article Clinical Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | South Africa |
| GeographicLocations_xml | – name: South Africa |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_UU_12023/27 |
| GroupedDBID | - 0R 0WA 123 186 1VV 29N 2KS 2WC 34G 39C 4 4.4 53G 55 5RE 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACRZS ADBBV ADBIT ADCBC AENEX AETEA AFFNX AFHKK AFKRA AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS ET EX3 F5P FD8 FM. FYUFA GJ GNUQQ GUQSH HCIFZ HZ I4R IH2 K-O KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MVM N9A NAPCQ NEJ O9- OK1 OMK OVD P-O P-S P2P PADUT PCD PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TEORI TN5 TUQ TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZR0 --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 36B AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ACKOT ACPFK ADRHT ADUKH AERZD AFOSN AGHSJ ALIPV BYPQX CCPQU CITATION H13 HF~ HMCUK HZ~ N4W PHGZM PHGZT PSYQQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7XB BEC K0Y MBDVC PKEHL Q9U 7X8 PUEGO |
| ID | FETCH-LOGICAL-c456t-ce04ce302be0816f3db37ee4cb5317ac5493c41a81a7b8167d806f2d7da5843d3 |
| IEDL.DBID | 7X7 |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Sun Aug 24 04:10:40 EDT 2025 Sat Aug 23 13:30:13 EDT 2025 Mon Jul 21 06:05:13 EDT 2025 Tue Jul 01 01:43:29 EDT 2025 Thu Apr 24 23:01:49 EDT 2025 Tue Dec 21 14:38:54 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | http://www.nejmgroup.org/legal/terms-of-use.htm Copyright © 2020 Massachusetts Medical Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c456t-ce04ce302be0816f3db37ee4cb5317ac5493c41a81a7b8167d806f2d7da5843d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://www.nejm.org/doi/pdf/10.1056/NEJMoa1901814?articleTools=true |
| PMID | 32130813 |
| PQID | 2371543053 |
| PQPubID | 40644 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2371860818 proquest_journals_2371543053 pubmed_primary_32130813 crossref_primary_10_1056_NEJMoa1901814 crossref_citationtrail_10_1056_NEJMoa1901814 mms_nejm_10_1056_NEJMoa1901814 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20200305 2020-03-05 |
| PublicationDateYYYYMMDD | 2020-03-05 |
| PublicationDate_xml | – month: 03 year: 2020 text: 20200305 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2020 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | Schnippel, K, Ndjeka, N, Maartens, G (r008) 2018; 6 Singh, R, Manjunatha, U, Boshoff, HI (r011) 2008; 322 Ismail, NA, Omar, SV, Joseph, L (r019) 2018; 28 r020 r001 Gandhi, NR, Andrews, JR, Brust, JC (r002) 2012; 16 Nunn, AJ, Phillips, PPJ, Meredith, SK (r003) 2019; 380 Stover, CK, Warrener, P, VanDevanter, DR (r014) 2000; 405 r017 r018 Yang, JS, Kim, KJ, Choi, H, Lee, SH (r010) 2018; 38 Haagsma, AC, Abdillahi-Ibrahim, R, Wagner, MJ (r006) 2009; 53 Gandhi, NR, Moll, A, Sturm, AW (r004) 2006; 368 Tyagi, S, Nuermberger, E, Yoshimatsu, T (r013) 2005; 49 Mbuagbaw, L, Guglielmetti, L, Hewison, C (r022) 2019; 25 Lee, M, Lee, J, Carroll, MW (r009) 2012; 367 O’Donnell, MR, Padayatchi, N, Kvasnovsky, C, Werner, L, Master, I, Horsburgh, CR (r005) 2013; 19 (r021) 2018; 392 Merle, CS, Fielding, K, Sow, OB (r027) 2014; 371 Jindani, A, Harrison, TS, Nunn, AJ (r026) 2014; 371 Diacon, AH, Dawson, R, von Groote-Bidlingmaier, F (r015) 2012; 380 Pym, AS, Diacon, AH, Tang, SJ (r007) 2016; 47 Nunn, AJ, Phillips, PP, Mitchison, DA (r024) 2010; 14 Cherry, CL, Wesselingh, SL, Lal, L, McArthur, JC (r016) 2005; 65 Olayanju, O, Limberis, J, Esmail, A (r023) 2018; 51 Gillespie, SH, Crook, AM, McHugh, TD (r025) 2014; 371 Manjunatha, U, Boshoff, HI, Barry, CE (r012) 2009; 2 e_1_3_5_28_2 e_1_3_5_27_2 e_1_3_5_26_2 e_1_3_5_24_2 e_1_3_5_23_2 e_1_3_5_22_2 e_1_3_5_21_2 e_1_3_5_2_2 e_1_3_5_8_2 e_1_3_5_20_2 e_1_3_5_7_2 e_1_3_5_9_2 e_1_3_5_4_2 e_1_3_5_3_2 e_1_3_5_6_2 Nunn AJ (e_1_3_5_25_2) 2010; 14 e_1_3_5_5_2 e_1_3_5_17_2 e_1_3_5_16_2 e_1_3_5_15_2 e_1_3_5_14_2 e_1_3_5_12_2 e_1_3_5_13_2 e_1_3_5_10_2 e_1_3_5_11_2 e_1_3_5_19_2 e_1_3_5_18_2 32130819 - N Engl J Med. 2020 Mar 5;382(10):959-960. doi: 10.1056/NEJMe2000860. 32521141 - N Engl J Med. 2020 Jun 11;382(24):2376. doi: 10.1056/NEJMc2009939. 32521142 - N Engl J Med. 2020 Jun 11;382(24):2376-2377. doi: 10.1056/NEJMc2009939. |
| References_xml | – volume: 380 start-page: 986 year: 2012 end-page: 993 ident: r015 article-title: 14-Day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. publication-title: Lancet – volume: 322 start-page: 1392 year: 2008 end-page: 1395 ident: r011 article-title: PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. publication-title: Science – volume: 380 start-page: 1201 year: 2019 end-page: 1213 ident: r003 article-title: A trial of a shorter regimen for rifampin-resistant tuberculosis. publication-title: N Engl J Med – volume: 14 start-page: 241 year: 2010 end-page: 242 ident: r024 article-title: Timing of relapse in short-course chemotherapy trials for tuberculosis. publication-title: Int J Tuberc Lung Dis – volume: 53 start-page: 1290 year: 2009 end-page: 1292 ident: r006 article-title: Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. publication-title: Antimicrob Agents Chemother – ident: r001 article-title: The end TB strategy. Geneva: World Health Organization, 2014 ( http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1 ) – volume: 49 start-page: 2289 year: 2005 end-page: 2293 ident: r013 article-title: Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. publication-title: Antimicrob Agents Chemother – volume: 65 start-page: 1778 year: 2005 end-page: 1781 ident: r016 article-title: Evaluation of a clinical screening tool for HIV-associated sensory neuropathies. publication-title: Neurology – volume: 25 start-page: 936 year: 2019 end-page: 943 ident: r022 article-title: Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. publication-title: Emerg Infect Dis – volume: 19 start-page: 416 year: 2013 end-page: 424 ident: r005 article-title: Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. publication-title: Emerg Infect Dis – ident: r018 article-title: Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2018 ( https://www.who.int/tb/publications/2018/WHO_technical_report_concentrations_TB_drug_susceptibility/en/ ) – volume: 368 start-page: 1575 year: 2006 end-page: 1580 ident: r004 article-title: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. publication-title: Lancet – volume: 392 start-page: 821 year: 2018 end-page: 834 ident: r021 article-title: Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. publication-title: Lancet ;The Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017 – volume: 51 start-page: 1800544 issue: 5 year: 2018 end-page: 1800544 ident: r023 article-title: Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. publication-title: Eur Respir J – ident: r020 article-title: WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019 ( https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf ) – volume: 405 start-page: 962 year: 2000 end-page: 966 ident: r014 article-title: A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. publication-title: Nature – volume: 6 start-page: 699 year: 2018 end-page: 706 ident: r008 article-title: Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. publication-title: Lancet Respir Med – volume: 28 start-page: 136 year: 2018 end-page: 142 ident: r019 article-title: Defining bedaquiline susceptibility, resistance, cross-resistance and associated genetic determinants: a retrospective cohort study. publication-title: EBioMedicine – volume: 47 start-page: 564 year: 2016 end-page: 574 ident: r007 article-title: Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. publication-title: Eur Respir J – volume: 16 start-page: 90 year: 2012 end-page: 97 ident: r002 article-title: Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. publication-title: Int J Tuberc Lung Dis – volume: 371 start-page: 1577 year: 2014 end-page: 1587 ident: r025 article-title: Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. publication-title: N Engl J Med – volume: 371 start-page: 1599 year: 2014 end-page: 1608 ident: r026 article-title: High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. publication-title: N Engl J Med – volume: 371 start-page: 1588 year: 2014 end-page: 1598 ident: r027 article-title: A four-month gatifloxacin-containing regimen for treating tuberculosis. publication-title: N Engl J Med – volume: 38 start-page: 563 year: 2018 end-page: 568 ident: r010 article-title: Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. publication-title: Ann Lab Med – volume: 2 start-page: 215 year: 2009 end-page: 218 ident: r012 article-title: The mechanism of action of PA-824: novel insights from transcriptional profiling. publication-title: Commun Integr Biol – ident: r017 article-title: National Institute of Allergy and Infectious Diseases. Division of Microbiology and Infectious Diseases (DMID) adult toxicity table November 2007 draft ( https://www.niaid.nih.gov/sites/default/files/dmidadulttox.pdf ) – volume: 367 start-page: 1508 year: 2012 end-page: 1518 ident: r009 article-title: Linezolid for treatment of chronic extensively drug-resistant tuberculosis. publication-title: N Engl J Med – volume: 14 start-page: 241 year: 2010 ident: e_1_3_5_25_2 article-title: Timing of relapse in short-course chemotherapy trials for tuberculosis. publication-title: Int J Tuberc Lung Dis – ident: e_1_3_5_12_2 doi: 10.1126/science.1164571 – ident: e_1_3_5_7_2 doi: 10.1128/AAC.01393-08 – ident: e_1_3_5_28_2 doi: 10.1056/NEJMoa1315817 – ident: e_1_3_5_3_2 doi: 10.5588/ijtld.11.0153 – ident: e_1_3_5_9_2 doi: 10.1016/S2213-2600(18)30235-2 – ident: e_1_3_5_22_2 doi: 10.1016/S0140-6736(18)31644-1 – ident: e_1_3_5_11_2 doi: 10.3343/alm.2018.38.6.563 – ident: e_1_3_5_10_2 doi: 10.1056/NEJMoa1201964 – ident: e_1_3_5_23_2 doi: 10.3201/eid2505.181823 – ident: e_1_3_5_6_2 doi: 10.3201/eid1903.120998 – ident: e_1_3_5_14_2 doi: 10.1128/AAC.49.6.2289-2293.2005 – ident: e_1_3_5_4_2 doi: 10.1056/NEJMoa1811867 – ident: e_1_3_5_19_2 – ident: e_1_3_5_13_2 doi: 10.4161/cib.2.3.7926 – ident: e_1_3_5_24_2 doi: 10.1183/13993003.00544-2018 – ident: e_1_3_5_27_2 doi: 10.1056/NEJMoa1314210 – ident: e_1_3_5_20_2 doi: 10.1016/j.ebiom.2018.01.005 – ident: e_1_3_5_5_2 doi: 10.1016/S0140-6736(06)69573-1 – ident: e_1_3_5_21_2 – ident: e_1_3_5_26_2 doi: 10.1056/NEJMoa1407426 – ident: e_1_3_5_8_2 doi: 10.1183/13993003.00724-2015 – ident: e_1_3_5_18_2 – ident: e_1_3_5_15_2 doi: 10.1038/35016103 – ident: e_1_3_5_17_2 doi: 10.1212/01.wnl.0000187119.33075.41 – ident: e_1_3_5_2_2 – ident: e_1_3_5_16_2 doi: 10.1016/S0140-6736(12)61080-0 – reference: 32521141 - N Engl J Med. 2020 Jun 11;382(24):2376. doi: 10.1056/NEJMc2009939. – reference: 32130819 - N Engl J Med. 2020 Mar 5;382(10):959-960. doi: 10.1056/NEJMe2000860. – reference: 32521142 - N Engl J Med. 2020 Jun 11;382(24):2376-2377. doi: 10.1056/NEJMc2009939. |
| SSID | ssj0000149 |
| Score | 2.7156408 |
| Snippet | Treatment options for highly drug-resistant tuberculosis are limited. In this study in South Africa, a new agent, pretomanid, was combined with bedaquiline and... Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes. In an open-label,... BackgroundPatients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.MethodsIn an... Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.BACKGROUNDPatients with highly... |
| SourceID | proquest pubmed crossref mms |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 893 |
| SubjectTerms | Administration, Oral Adolescent Adult Antitubercular Agents - administration & dosage Antitubercular Agents - adverse effects Bacterial infections Bacterial Load Bactericidal activity Diarylquinolines - administration & dosage Diarylquinolines - adverse effects Drug dosages Drug resistance Drug Therapy, Combination Enrollments Extensively Drug-Resistant Tuberculosis - drug therapy Extensively Drug-Resistant Tuberculosis - mortality FDA approval Female Humans Intention to Treat Analysis Laboratories Linezolid Linezolid - administration & dosage Linezolid - adverse effects Male Middle Aged Multidrug resistance Mycobacterium tuberculosis - isolation & purification Myelosuppression Nitroimidazoles - administration & dosage Nitroimidazoles - adverse effects Oral administration Patients Peripheral neuropathy Protein synthesis Safety Treatment Outcome Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Pulmonary - drug therapy Young Adult |
| Title | Treatment of Highly Drug-Resistant Pulmonary Tuberculosis |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa1901814 https://www.ncbi.nlm.nih.gov/pubmed/32130813 https://www.proquest.com/docview/2371543053 https://www.proquest.com/docview/2371860818 |
| Volume | 382 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Pa8IwFH5MhbHL2O-5Oelg7LSgbWLTnsbmFBlMRBS8lTRNB6O2Tu3B_34vNbp5cJdc8gjh5cf3Je_xPYCHKKSui0BPeCw4YYr7xI-5Iq5UftOPfOmoIsu37_bG7H3SmpgPt4VJq9zcicVFHWVS_5E3HMoR7XF30ufZN9FVo3R01ZTQKEFFS5fpxxef8D_yUYb-mh8ko7GJmN_QleYzodHQs9kOJpWm08V-ulnATvcEjg1ftF7WC3wKByo9g8MPExE_B3-0yRS3stjSWRvJynqb559kqBaaG2LHIE9w9mK-skZ5qOYyTzLsuoBxtzNq94gph0AkspwlkarJpKJNJ1S6WkZM0c9cKSZDPEdcSHzpUcls4dmCh2jAI6_pxk7EI4Esg0b0EspplqprsCKfxSELhbRxTOZRD0ldS0vRM9uWVLpVeNo4JJBGK1yXrEiCImbdcoMd_1XhcWs-W4tk7DOso3eDVH1N9xnUNo4PzGFaBL9LX4X7bTceAx3bEKnK8rWN52p9vipcrRdsOxXqIFB7Nr35f_BbOHL0Y1onmLVqUF7Oc3WHjGMZ1ottha3XtutQee30B8MfH__R2w |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JTsMwEB2xSMAFsVPWIAEnLJrYjZMDQohFZRVCReIWHGeChNoE2kaoP8U3Ms5S4FBunD2yrMmz59kzeQOwG4XcdSnQMxkryQRKn_mxROZq9Ot-5GsH8yrfO7f5KK6eGk9j8Fn9C2PKKqszMT-oo1SbN_JDh0uK9oROfvz2zkzXKJNdrVpoFLC4xsEHXdl6R5dn9H33HOfivHXaZGVXAaaJLPSZxrrQyOtOiKbpRMxpuRJR6JDgKJWmCxPXwlaerWRIBjLy6m7sRDJSFKx5xGnecZgUnEuj1e-d2j_kqkq6Xb5YlZqexDEOTWf7VJno69niVwwc73R6o-ltHuYu5mC25KfWSQGoeRjDZAGmbssM_CL4raoy3Upjy1SJtAfWWTd7YQ_YM1yUBu6zNnlLdQdWKwuxq7N2SkNL8PgvjlqGiSRNcBWsyBdxKEKlbZpTeNwjEtkw0vfCtjXXbg0OKocEutQmNy0y2kGeI2-4wS__1WB_aP5WiHKMMtwi7wYJvnZGGWxUjg_KzdsLvqFWg53hMG07k0tRCaZZYeO5Rg-wBivFBxsuhTtEDDybr_09-TZMN1u3N8HN5d31Osw45iJvitsaGzDR72a4SWynH27lELPg-b8x_QVdCwxC |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1La9tAEB7ygJBLafN04zoKtDllsaVda6VDKaWOyashBAd8U1arUSDYUmJbFP-1_rrOSis3OTi3nHdYltG3-327M5oB-JrE3PeJ6JlMlWQCZcjCVCLzNYadMAm1h2WW77V_dicuht3hCvyt_4UxaZX1mVge1EmuzRt52-OS2J7QydupTYu46fV_PD0z00HKRFrrdhoVRC5x_oeub9Pv5z361t88r386-HXGbIcBpkk4zJjGjtDIO16MpgFFymnpElHomKAplabLE9fCVYGrZEwGMgk6fuolMlFE3DzhNO8qrEtOtEl7SQ7li9JVVnrb1ytb35P0Rtt0uc-VYeLAFa_4cHU8ni6XuiXl9T_CB6tVnZ8VuD7BCmZbsPHbRuO3IRzUWepOnjomY2Q0d3qT4oHd4tToUhq4KUbkLTWZO4MixokuRjkN7cDduzhqF9ayPMN9cJJQpLGIlXZpThHwgARl15TBF66rufYbcFI7JNK2TrlplzGKynh5149e-a8Bxwvzp6pAxzLDFnk3yvBxvMygWTs-sht5Gv2HXQOOFsO0BU1cRWWYF5VN4JvagA3Yqz7YYincI5EQuPzz25MfwgahObo6v748gE3P3OlNnlu3CWuzSYFfSPjM4laJMAfu3xvS_wAqLBCk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+of+Highly+Drug-Resistant+Pulmonary+Tuberculosis&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Conradie+Francesca&rft.au=Diacon%2C+Andreas+H&rft.au=Ngubane+Nosipho&rft.au=Howell%2C+Pauline&rft.date=2020-03-05&rft.pub=Massachusetts+Medical+Society&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=382&rft.issue=10&rft.spage=893&rft.epage=902&rft_id=info:doi/10.1056%2FNEJMoa1901814&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |